Business
AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift
AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift Canada New...
About this update from Ventripoint Diagnostics Ltd.
[{"type":"text","content":"\n\n\nAI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\nCanada NewsWire\n\n\nIssued on behalf of VentriPoint Diagnostics Ltd.\nVANCOUVER, BC, Jan. 29, 2026 /CNW/ -- Equity-Insider.com News Commentary – The global AI medical imaging market exploded to a staggering $2.57 trillion in 2026 as the entire healthcare ecosystem ditched trial-and-error medicine for AI-native diagnostic precision and autonomous operations[1]. This massive movement has pushed the AI drug discovery sector to $1.81 billion, powered by \"federated learning\" models that use high-frequency sensing to collapse development timelines from years into months[2]. This new Diagnostic Data Core is creating massive tailwinds for VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), Recursion Pharmaceuticals (NASDAQ: RXRX), Tempus AI (NASDAQ: TEM), Schrodinger (NASDAQ: SDGR) and Eli Lilly (NYSE: LLY) as they bridge the gap between old-school hardware and high-fidelity digital control.\n\n\n\n\n\n\n\nBig data in healthcare has now reached a projected $132.32 billion in 2026, fueled by the urgent need for real-time, autonomous diagnostic resilience in every clinical workflow[3]. Simultaneously, digital pathology platforms have surged to $2.01 billion as AI-powered biomarker prediction becomes the primary value driver for software-as-a-service architectures[4]. We are witnessing a total \"diagnostic-edge\" convergence where MRI-grade software isn't just a tool—it's the primary engine for proactive life-extension and institutional ROI across the 2026 cycle.\nVentripoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF) is building a subscription business around technology that converts standard 2D ultrasound images into detailed 3D heart models with MRI-level accuracy. The system delivers precise cardiac assessments at a fraction of the cost and complexity of traditional MRI imaging.\nStrong investor demand recently doubled the company's private placement from $500,000 to $1 million. The capital will fund commerciali...